Fortress Biotech

Historical price data

Fortress Biotech operates as a biopharmaceutical accelerator, utilizing a flexible, therapeutic area-agnostic model to identify and advance high-potential assets. The company has achieved significant milestones, including the FDA approval of ZYCUBO® for Menkes disease and the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million. By developing products both internally and through a network of majority-owned and minority partner companies, Fortress aims to create a diversified, long-term revenue stream from commercial products, royalties, and equity stakes.

Fortress Biotech's core platform is its business development and operational engine, specializing in identifying, acquiring, and advancing biopharmaceutical assets through flexible deal structures and a network of partner companies, rather than a single scientific technology.

Total raised: $165M

Fortress competes with other biotech accelerators and venture capital firms for asset acquisition, and its individual programs face competition from large pharma and specialized biotechs in their respective therapeutic areas. Its primary differentiation is its flexible, capital-efficient business model that seeks to diversify risk and leverage expertise across a portfolio rather than betting on a single technology.